MAP2K7 and neoplasm: Confirming the potential interest of MEK inhibitors for the treatment of HGSC patients with high MAP3K8 protein levels, we observed that both MEK inhibitors markedly reduced tumour growth in high-MAP3K8 PDX models (Fig. 5g,i; Supplementary Fig. 7D,E), compared with low- or intermediate-MAP3K8 PDX models (Fig. 5h,j; Supplementary Fig. 7F).